Laura Isabel Vázquez-Carrillo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Laura Isabel Vázquez-Carrillo has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
- Alejandro A. Camacho-Davila
Facultad de Ciencias Químicas Universidad Autónoma de Chihuahua Chihuahua Chihuahua Mexico
1 shared publication - Alfonso Salgado-Aguayo
Laboratorio de Investigación en Enfermedades Reumáticas, Instituto Nacional de Enfermedades Respiratorias, Ciudad de México 14080, Mexico
1 shared publication - César López-Camarillo
Posgrado en Ciencias Genómicas, Universidad Autónoma de la Ciudad de México, Mexico City 03100, Mexico
1 shared publication - Elisa Elvira Figueroa-Angulo
Laboratorio de Patogenesis Celular y Molecular Humana y Veterinaria, Posgrado en Ciencias Genomicas, Universidad Autonoma de la Ciudad de Mexico, San Lorenzo 290, Colonia del Valle, Delegación Benito Juárez México, Mexico City 03100, Mexico
1 shared publication - Jonathan Puente-Rivera
División de Investigación, Hospital Juárez de México, Mexico City 07760, Mexico
1 shared publication - José Carlos Espinoza Hicks
Facultad de Ciencias Químicas Universidad Autónoma de Chihuahua Chihuahua Chihuahua Mexico
1 shared publication
Latest Publications
- Open Access
- 5 June 2025
- Published by MDPI AG in Scientia Pharmaceutica
- Vol. 93 (2) , 25
Prenylated Chalcones as Anticancer Agents Against Castration-Resistant Prostate Cancer
Prenylated chalcones have garnered attention as potential anticancer agents due to their ability to modulate multiple cancer-related pathways. In this study, we synthesized and evaluated nine novel prenylated chalcone derivatives for their antiproliferative effects against castration-resistant prostate cancer (CRPC) cell lines, DU145 and PC3. Among these, compounds 6d and 7j demonstrated potent cytotoxic activity, with IC50 values comparable to cisplatin, and exhibited selective toxicity towards cancer cells over non-tumorigenic RWPE-1 cells. Mechanistic investigations revealed that these compounds induce apoptosis via mitochondrial membrane depolarization and increased late apoptotic events. Flow cytometry confirmed activation of both early and late apoptotic pathways. These findings highlight the potential of chalcone derivatives 6d and 7j as promising therapeutic candidates for CRPC treatment and support further development of chalcone-based molecules in precision oncology.
- 5 June 2025
- Published by MDPI AG in Scientia Pharmaceutica
- Vol. 93 (2) , 25
Open AccessPrenylated Chalcones as Anticancer Agents Against Castration-Resistant Prostate Cancer
Prenylated chalcones have garnered attention as potential anticancer agents due to their ability to modulate multiple cancer-related pathways. In this study, we synthesized and evaluated nine novel prenylated chalcone derivatives for their antiproliferative effects against castration-resistant prostate cancer (CRPC) cell lines, DU145 and PC3. Among these, compounds 6d and 7j demonstrated potent cytotoxic activity, with IC50 values comparable to cisplatin, and exhibited selective toxicity towards cancer cells over non-tumorigenic RWPE-1 cells. Mechanistic investigations revealed that these compounds induce apoptosis via mitochondrial membrane depolarization and increased late apoptotic events. Flow cytometry confirmed activation of both early and late apoptotic pathways. These findings highlight the potential of chalcone derivatives 6d and 7j as promising therapeutic candidates for CRPC treatment and support further development of chalcone-based molecules in precision oncology.